Forge Genetics Ltd.

Forge Genetics Ltd. is a biotechnology company focusing on genetic research to enhance agricultural productivity through innovative testing solutions. Forge Genetics Ltd. specializes in biodiscovery, offering advanced genetic testing services to improve crop resilience.

Founded in 2023 in Nottingham, UK, the company has completed 1 deal as of March 5, 2025. In its latest ANGEL funding round, it raised GBP 240,000, equating to the total amount raised. In September 2025, Forge Genetics Ltd. raised GBP 2 million in venture funding from new investor Mercia Asset Management.

Forge Genetics Ltd specializes in advanced biodiscovery solutions, focusing on genetic research and biotechnology applications. The company’s core offerings include innovative genetic testing services designed to enhance agricultural productivity and improve crop resilience. These products serve a range of end users, including agricultural producers and research institutions, aimed at addressing challenges such as pest resistance and climate adaptability in crops. Forge Genetics operates primarily in the European and North American markets, where the demand for sustainable agricultural practices is growing.

By leveraging technology, the company's products enable clients to optimize their operations and yield, thus contributing to the overall efficiency and sustainability of agricultural practices. Forge Genetics Ltd generates revenue through a structured business model that emphasizes partnerships with agricultural and research organizations. Transactions typically occur as direct collaborations or service agreements, where clients engage the company for customized genetic testing and consultation services. Revenue streams include fee-for-service arrangements, subscription models for ongoing genetic analysis, and potential licensing agreements for proprietary technologies.

The pricing structure reflects the complexity and specificity of the services, with flagship offerings positioned to deliver high value to clients in the agriculture sector. This model facilitates long-term relationships, ensuring clients receive ongoing support in their biodiscovery initiatives. The company will use the September 2025 funding to develop its gene editing tool, hire more staff, and prepare for clinical trials.